组织纤溶酶原激活剂

急性白血病血浆组织纤溶酶原激活剂及其抑制剂活性的测定

Clinical significance of determination of t-PA and Pai activity in plasma of patients with acute leukemia

RT-PCR测定组织纤溶酶原激活剂突变体（La-tPA）在转基因鼠乳腺表达的研究

La tRA Expression Determination by RT PCR in Mammary Gland of Transgenic Mice

纤溶酶原激活物抑制物、组织纤溶酶原激活剂、血栓素B2及6-酮-前列腺素F（1α）对糖尿病视网膜病变早期诊断的临床意义

Clinical significance of plasminogen activator inhibitor , tissue plasminogen activator , thromboxane B_2 and 6-Ketosteroid-prostaglandin F_ ( 1 α) in early diagnosis of diabetic retinopathy

抗PAI抑制作用的组织纤溶酶原激活剂在大肠杆菌中的表达

Expression and activity of tissue-type plasminogen activator mutant reteplase with deletion of PAI-1 binding sites

应用发色底物比色分析法，对42例正常人和52例急性白血病（AL）病人血浆组织纤溶酶原激活剂（t-PA）、组织纤溶酶原激活剂抑制剂（PAI）活性进行了检测。

We detected plasma tissue plasminogen activator ( t-PA ) and plasminogen activator Inhibitor ( PAI ) activity in 52 patients with acute leukemia ( AL ) by a chromogenic substrate method .

目的：探讨T2DM患者血浆组织纤溶酶原激活剂（t-pA）、组织纤溶酶原激活剂抑制剂（PAI）活性和D-二聚体（D-dimer）水平变化及意义。

Objective : To investigate the change in tissue plasminogen activator ( t-pA ), plasminogen activator inhibitor and the D-dimer level in T 2 DM patient plasma .

材料和方法：35例AMI患者被分为接受静脉内组织纤溶酶原激活剂的IVT组，接受急症经皮冠脉成形术的PTCA和IVT＋PTCA组。

Materials and Methods : Thirty five AMI patients were classified into intravenous thrombolysis ( IVT ) group , percutaneous transluminal coronary angioplasty ( PTCA ) group , and IVT + PTCA group .

检测治疗前和治疗后2周时血浆组织纤溶酶原激活剂（tPA）活性、含量及其抑制物（PAI-1）活性。

Before and after 2 weeks of therapy , plasma activity and mass concentrations of tissue plasminogen activator ( tPA ), activity of plasminogen activator inhibitor 1 ( PAI 1 ) were measured in all patients .

直接注射组织纤溶酶原激活剂治疗视网膜下黄斑部出血

Management of subretinal macular haemorrhage by direct administration of tissue plasminogen activator

前房内注射组织纤溶酶原激活剂预防先天性白内障术后严重的纤维渗出

Intracameral tissue plasminogen activator to prevent severe fibrinous effusion after congenital cataract surgery

首批重组人组织纤溶酶原激活剂国家标准品的研制

Establishment and Standardization of the National Reference Standard of Recombinant Human Tissue Plasminogen Activator

重组型组织纤溶酶原激活剂治疗急性缺血性卒中后的止血激活和临床预后

Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke

重组人组织纤溶酶原激活剂治疗急性心肌梗死病人的护理

Nursing care of patients with acute myocardial infarction treated with recombinant human tissue plasminogen activator

少数2型糖尿病和肥胖青少年的纤溶酶原激活剂抑制因子-1和组织纤溶酶原激活剂

Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity

一种新的人组织纤溶酶原激活剂对急性心肌梗死的溶栓效果

Clinical Thrombolytic Trial of A New Type of Tissue-Plasminogen Activator in Patients with Acute Myocardial Infarction

肝炎患者血浆组织纤溶酶原激活剂及其抑制剂的变化

Study on Changes of Tissue Plasminogen Activator and It 's Inhibitor in Patients with Viral Hepatitis

组织纤溶酶原激活剂、肝素抑制人工晶体表面细胞学反应的实验对比研究

Experimental Contrast Study of Inhibiting Effects of Tpa VS Heparin on Cellular Response on Intraocular Lens Surface Following Surgery

重组组织纤溶酶原激活剂治疗急性缺血性卒中的性别差异：一个临床随机试验的汇总分析

Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke : A pooled analysis of randomized clinical trials

方法采用鼠非停滞模型，动态监测可溶性纤维蛋白单体复合物、纤维蛋白降解产物、D二聚体、组织纤溶酶原激活剂等指标的变化。

METHODS A non stasis rat model of thrombogenicity has been used . Prethrombotic markers , soluble fibrin monomer complex , fibrin degradation product , D dimer and tissue plasminogen activator were monitored .

定量检测组织型纤溶酶原激活剂夹心ELISA方法的建立

Establishment of a Sandwich ELISA for Quantitative Measurement of Tissue-type Plasminogen Activator

EGF对小鼠角质形成细胞中组织型纤溶酶原激活剂表达的调节

Regulation of tissue plasminogen activator expression by EGF in epidermal keratinocytes of mouse

MCF-7细胞中组织型纤溶酶原激活剂乳腺特异性表达载体的瞬时表达

Transient expression of tissue-type plasminogen activator in mammary carcinoma cell line MCF-7

组织型纤溶酶原激活剂（t-PA）及其突变体的表达研究进展

Progresses in the Expression of Tissue-Type Plasminogen Activator and Its Mutants

野生型组织型纤溶酶原激活剂（t-PA）工程细胞株生物学特性分析

The analysis of biological characteristics for the wild-type t-PA engineering cell lines

组织型纤溶酶原激活剂（t-PA）、纤溶酶原激活剂抑制剂（PAI）均是体内纤溶系统的重要组成部分。

PAI and t-PA are important constituents of fibrinolytic system in human body .

载脂蛋白AI、组织型纤溶酶原激活剂显著低于对照组（P＜0.001和P＜0.01）。

The concentration of Apo A I and t PA activity were obviously lower than those of the controls ( p < 0 001 and 0 01 , respectively ) .

组织型纤溶酶原激活剂&膜联蛋白A5融合基因的构建

Construction of Tissue Plasminogen Activator-annexin A5 Fusion Gene

组织型纤溶酶原激活剂（t-PA）对实验性青光眼滤过性手术瘢痕形成的影响

Effects of tissue plasminogen activator ( t-PA ) on scar formation after experimental filtration surgery

采用尿激酶（75万~150万U）或重组组织型纤溶酶原激活剂（50~100mg）溶栓。

Urokinase ( 750 ? 000 U-1 ? 500 ? 000 U ) and recombinant tissue-type plasminogen activator ( 50-100 mg ) were administered as thrombolytic agents .

本文建立了组织型纤溶酶原激活剂（t-PA）活力的发光固相测定方法。

A luminescence solid phase assay for tissue type plasminogen activator ( t-PA ) was developed .